# Nuclide record in-111-pentetreotide (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/in-111-pentetreotide/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "in-111-pentetreotide" ;
  schema:name "Indium-111 pentetreotide"@en ;
  schema:alternateName "111In-pentetreotide"@en, "OctreoScan"@en, "OctreoScan" ;
  schema:description "The original nuclear medicine scan for finding neuroendocrine tumours, used before PET scans like Ga-68 DOTATATE became available. It is still FDA-approved but has largely been superseded because PET gives sharper pictures with less radiation."@en ;
  schema:url <https://nuclide.cc/drugs/in-111-pentetreotide/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020314Orig1s000Lbl.pdf> ;
  nuclide:status "approved" ;
  nuclide:tag "SSTR2", "SPECT", "legacy agent" ;
  nuclide:modality "SPECT tracer" ;
  nuclide:approval "US 1994: Scintigraphic localisation of primary and metastatic neuroendocrine tumours bearing somatostatin receptors" ;
  nuclide:related <https://nuclide.cc/drugs/cu-64-dotatate/>, <https://nuclide.cc/drugs/ga-68-dotatoc/>, <https://nuclide.cc/drugs/ga68-dotatate/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/in-111/>, <https://nuclide.cc/isotopes/cu-64/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/pancreatic-net/>, <https://nuclide.cc/indications/small-intestinal-net/> ;
  nuclide:technologies <https://nuclide.cc/technologies/spect/>, <https://nuclide.cc/technologies/spect-ct/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:companies <https://nuclide.cc/companies/curium/> .